At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
In Brief
A Phase 2 clinical trial evaluating Flortaucipir F18 and Brain PET Scan for Alzheimer Disease. Completed, enrolled 155 participants across 10 sites in 2 countries.
Detailed Summary
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedOct 26, 2017
Enrollment StartNov 21, 2017
Primary CompletionAug 31, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.7 years ago
Interventions
Flortaucipir F18drug
370 megabecquerel (MBq) IV single-dose
Brain PET Scanprocedure
positron emission tomography (PET) scan of the brain